Skip to main content

31-08-2018 | Rheumatology | News | Article

News in brief

Support for minimal disease activity as treatment goal in PsA

medwireNews: Meeting the criteria for minimal disease activity (MDA) is associated with meaningful improvements in patient-reported outcomes among individuals with psoriatic arthritis (PsA), say researchers.

They analyzed an integrated database of the SPIRIT-P1 and SPIRIT-P2 trials, finding that the 152 participants who met the MDA criteria after 24 weeks of treatment with ixekizumab or placebo had significantly greater improvements in all eight domains of the 36-Item Short Form Health Survey than the 322 patients who did not achieve MDA.

Moreover, patients with an MDA response experienced significantly greater improvements in both the Health State Index and visual analog scale of the European Quality of Life 5 Dimension 5 Level Health Questionnaire, as well as in work-related functioning, than nonresponders.

“Taken together with previous findings showing improved physical functioning and reduced disease progression on MDA responders, these findings suggest that MDA response is a strong discriminator for achieving a desirable disease status based on both physician and patient reported outcomes in PsA,” conclude Laura Coates (University of Oxford, UK) and co-investigators in BMC Rheumatology.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

See the research in context now

with trial summaries, expert opinion and congress coverage